Integral PET Associates is joining forces with the University of Pennsylvania Cancer Center and Penn’s radiology department to extend its network of PET scanning centers. One of the largest cancer networks of its kind, the University of
Integral PET Associates is joining forces with the University of Pennsylvania Cancer Center and Penn’s radiology department to extend its network of PET scanning centers. One of the largest cancer networks of its kind, the University of Pennsylvania Cancer Network is composed of 28 hospitals and a large medical oncology network. Plans call for opening as many as seven PET centers at UPCN community hospitals within the next six months. Each Penn PET center will have a fixed PET scanner. Additional sites in the future may have fixed or mobile scanners, depending on patient demand. University physicians will help interpret the PET scans and oversee the medical aspects of the PET centers; Integral PET will perform administrative functions. The alliance was forged to address the complex educational, financial, medical, functional, and operational concerns that accompany the installation and operation of PET centers in community-based settings.
Study Reaffirms Low Risk for csPCa with Biopsy Omission After Negative Prostate MRI
December 19th 2024In a new study involving nearly 600 biopsy-naïve men, researchers found that only 4 percent of those with negative prostate MRI had clinically significant prostate cancer after three years of active monitoring.
Study Examines Impact of Deep Learning on Fast MRI Protocols for Knee Pain
December 17th 2024Ten-minute and five-minute knee MRI exams with compressed sequences facilitated by deep learning offered nearly equivalent sensitivity and specificity as an 18-minute conventional MRI knee exam, according to research presented recently at the RSNA conference.
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.